Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
Status:
Completed
Trial end date:
2019-02-04
Target enrollment:
Participant gender:
Summary
This phase III randomized trial compares three different peripheral stem cell mobilization
regimens for patients with multiple myeloma who have received primary induction therapy or
other therapies. Up to 180 patients will be enrolled. Patients eligible for treatment will be
randomized to one of the three following mobilization regimens:
Arm A = VELCADE, CYCLOPHOSPHAMIDE, & G-CSF Arm B = VELCADE & G-CSF Arm C = CYCLOPHOSPHAMIDE &
G-CSF Arm D = PLERIXAFOR & G-CSF Arm E = PLERIXAFOR, VELCADE, & G-CSF